Literature DB >> 25366592

Molecular basis for intracranial aneurysm formation.

Miyuki Fukuda1, Tomohiro Aoki.   

Abstract

Intracranial aneurysm (IA) is a socially important disease both because it has a high prevalence and because of the severity of resultant subarachnoid hemorrhages after IA rupture. The major concern of current IA treatment is the lack medical therapies that are less invasive than surgical procedures for many patients. The current situation is mostly caused by a lack of knowledge regarding the regulating mechanisms of IA formation. Hemodynamic stress, especially high wall shear stress, loaded on arterial bifurcation sites is recognized as a trigger of IA formation from studies performed in the field of fluid dynamics. On the other hand, many studies using human specimens have also revealed the presence of active inflammatory responses, such as the infiltration of macrophages, in the pathogenesis of IA. Because of these findings, recent experimental studies, mainly using animal models of IA, have revealed some of the molecular mechanisms linking hemodynamic stress and long-lasting inflammation in IA walls. Currently, we propose that IA is a chronic inflammatory disease regulated by a positive feedback loop consisting of the cyclooxygenase (COX)-2 - prostaglandin (PG) E2 - prostaglandin E receptor 2 (EP2) - nuclear factor (NF)-κB signaling pathway triggered under hemodynamic stress and macrophage infiltration via NF-κB-mediated monocyte chemoattractant protein (MCP)-1 induction. These findings indicate future directions for the development of therapeutic drugs for IAs.

Entities:  

Mesh:

Year:  2015        PMID: 25366592     DOI: 10.1007/978-3-319-04981-6_2

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  6 in total

1.  A sphingosine-1-phosphate receptor type 1 agonist, ASP4058, suppresses intracranial aneurysm through promoting endothelial integrity and blocking macrophage transmigration.

Authors:  Rie Yamamoto; Tomohiro Aoki; Hirokazu Koseki; Miyuki Fukuda; Jun Hirose; Keiichi Tsuji; Katsumi Takizawa; Shinichiro Nakamura; Haruka Miyata; Nozomu Hamakawa; Hidetoshi Kasuya; Kazuhiko Nozaki; Yoshitaka Hirayama; Ichiro Aramori; Shuh Narumiya
Journal:  Br J Pharmacol       Date:  2017-05-27       Impact factor: 8.739

2.  New Pathophysiological Considerations on Cerebral Aneurysms.

Authors:  Keun-Hwa Jung
Journal:  Neurointervention       Date:  2018-08-31

3.  RNA sequencing analysis revealed the induction of CCL3 expression in human intracranial aneurysms.

Authors:  Tomohiro Aoki; Hirokazu Koseki; Haruka Miyata; Masayoshi Itoh; Hideya Kawaji; Katsumi Takizawa; Akitsugu Kawashima; Hiroshi Ujiie; Takashi Higa; Kenzo Minamimura; Toshikazu Kimura; Hidetoshi Kasuya; Kazuhiko Nozaki; Akio Morita; Hirotoshi Sano; Shuh Narumiya
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

4.  Pharmacological inhibition of STAT3 by BP-1-102 inhibits intracranial aneurysm formation and rupture in mice through modulating inflammatory response.

Authors:  Zhixian Jiang; Jiaxin Huang; Lingtong You; Jinning Zhang; Bingyu Li
Journal:  Pharmacol Res Perspect       Date:  2021-02

5.  T cell function is dispensable for intracranial aneurysm formation and progression.

Authors:  Haruka Miyata; Hirokazu Koseki; Katsumi Takizawa; Hidetoshi Kasuya; Kazuhiko Nozaki; Shuh Narumiya; Tomohiro Aoki
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

6.  Eicosapentaenoic acid prevents the progression of intracranial aneurysms in rats.

Authors:  Yu Abekura; Isao Ono; Akitsugu Kawashima; Katsumi Takizawa; Hirokazu Koseki; Haruka Miyata; Kampei Shimizu; Mieko Oka; Mika Kushamae; Susumu Miyamoto; Hiroharu Kataoka; Akira Ishii; Tomohiro Aoki
Journal:  J Neuroinflammation       Date:  2020-04-24       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.